WNWeiqi Nian

Weiqi Nian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weiqi Nian has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • AP-site-containing duplex-enabled autocatalytic CRISPR-Cas12a circuits for ultrasensitive APE1 detection

    by Yang Song, Juan Long, Dan Zhao, Huaibi Wang, Wanyan Tang, Wei Yang, Yu Zheng, Rui Yuan, Decai Zhang, Guanmin Jiang, et al.

  • Approaches for Detecting Protein S -Palmitoylation and Depalmitoylation

    by Changyang Tang, Jiaorui Peng, Chunyang Xie, Wenyan Wu, Tingxiu Xiang, Weiqi Nian, Rui Yuan, Aimin Yang

    Protein S-palmitoylation is the thioesterification of a 16-carbon saturated fatty acid (palmitate) to specific cysteine residues. Unlike other protein lipidation events, including N-myristoylation,...


  • Open Access

    Bufalin inhibits hepatocellular carcinoma progression by blocking EGFR-mediated RAS-RAF-MEK-ERK pathway activation

    by Jingwen Liu, Jia Jiang, Ju Huang, Zhi-E Fang, Lexi Liu, Yong Liu, Weiqi Nian, Jianyuan Tang, Zhilei Wang

    Background: Hepatocellular carcinoma (HCC) remains one of the most challenging malignancies with persistently dismal long-term survival outcomes despite multidisciplinary advances in diagnostic and therapeutic strategies. Cinobufacini preparations have garnered increasing attention as adjunctive therapeutic agents in integrated management strategies for HCC. Bufalin (BF), the active ingredient in Cinobufacini, has garnered substantial attention due to its potent antitumor effects. However, the precise molecular mechanisms underlying its antitumor actions remain incompletely characterized. Methods: A clinical retrospective cohort analysis was conducted to establish the definitive clinical benefit of Cinobufacini in improving treatment outcomes among HCC patients. Building upon these clinical insights, a multi-dimensional approach was implemented to elucidate the anti-HCC molecular mechanisms mediated by the bioactive component BF of Cinobufacini. Results: Western medical treatment combined with Cinobufacini shows an improving trend in the overall survival (OS) and progression free survival (PFS) of HCC patients. Moreover, our exploratory analysis suggests a potential dose-response relationship where longer cumulative exposure to Cinobufacini appears to be associated with improved clinical outcomes. In vitro experiments demonstrated that BF significantly inhibited cell viability and proliferation, and induced apoptosis in HepG2 and HCCLM3. Network pharmacology analysis identified 20 core targets, and molecular docking revealed high-affinity binding between BF and key proteins, including EGFR, GRB2, SRC, and MAPK1. HCC tissue microarrays confirmed the overexpression of EGFR and GRB2 in HCC tissues. Further mechanistic investigations revealed that BF suppressed the EGFR-mediated RAS/RAF/MEK/ERK pathway activation in HepG2 and HCCLM3. BF intervention significantly reduced tumor volumes in C57BL/6 mouse subcutaneous HCC xenograft and BALB/c Nude mouse orthotopic HCC xenograft models. Moreover, BF inhibited the phosphorylation levels of EGFR, RAF, MEK, and ERK in tumor tissues, further corroborating its inhibitory effects on the RAS/RAF/MEK/ERK signaling pathway. Conclusions: Our observational data suggest a potential association between Cinobufacini use and favorable trends in OS and PFS among HCC patients. BF exerts its antitumor effects against HCC by interfering with the EGFR-mediated RAS/RAF/MEK/ERK signaling pathway. These findings not only elucidate the molecular mechanisms underlying the antitumor actions of BF but also highlight the potential of Cinobufacini preparations as a valuable therapeutic option for HCC.


  • High-efficiency detection of APE1 using a defective PAM-driven CRISPR-Cas12a self-catalytic biosensor

    by Yang Song, Juan Long, Huaibi Wang, Wanyan Tang, Wei Yang, Yu Zheng, Rui Yuan, Decai Zhang, Bing Gu, Weiqi Nian


  • Synthesis and structural modification of the natural product Ivesinol to discover novel autophagy activators

    by Zhi-Peng Wang, Wenxin You, Jie Peng, Biao Xu, Xiaohong Yang, Wanyan Tang, Yun He, Aimin Yang, Chao Yu, Weiqi Nian


  • Open Access

    Electrochemical Biosensors for Circulating Tumor DNA Detection

    by Ke Wang, Zhijia Peng, Xiaogang Lin, Weiqi Nian, Xiaodong Zheng, Jayne Wu

    Early diagnosis and treatment have always been highly desired in the fight against cancer, and detection of circulating tumor DNA (ctDNA) has recently been touted as highly promising for early cancer-screening. Consequently, the detection of ctDNA in liquid biopsy is gaining much attention in the field of tumor diagnosis and treatment, which has also attracted research interest from industry. However, it is difficult to achieve low-cost, real-time, and portable measurement of ctDNA in traditional gene-detection technology. Electrochemical biosensors have become a highly promising solution to ctDNA detection due to their unique advantages such as high sensitivity, high specificity, low cost, and good portability. Therefore, this review aims to discuss the latest developments in biosensors for minimally invasive, rapid, and real-time ctDNA detection. Various ctDNA sensors are reviewed with respect to their choices of receptor probes, designs of electrodes, detection strategies, preparation of samples, and figures of merit, sorted by type of electrode surface recognition elements. The development of biosensors for the Internet of Things, point-of-care testing, big data, and big health is analyzed, with a focus on their portable, real-time, and non-destructive characteristics.


  • Palindromic-assisted self-annealing transcription amplification for reliable genotyping of epidermal growth factor receptor exon mutations

    by Rui Yuan, Wanyan Tang, Hong Zhang, Wenxin You, Xiaolin Hu, Haiwei Zhang, Ling Chen, Weiqi Nian, Shijia Ding, Yang Luo


  • Open Access

    Progress on Preparation of pH/Temperature-Sensitive Intelligent Hydrogels and Applications in Target Transport and Controlled Release of Drugs

    by Lixian Li, Yongpeng He, Xiaodong Zheng, Lin Yi, Weiqi Nian

    Hydrogels with three-dimensional network structure, hydrophilic, and insoluble in water which are ideal carrier materials for intelligent drug delivery systems. Intelligent hydrogel has become a research frontier and hotspot because of its intelligence, high efficiency, safety, and convenience in drug controlled and prolonged release. It has a broad application prospect in the medicine and biomedicine fields and can lead the medicine fields into a new era of “precise treatment.” Based on the latest research progress, the main preparation methods of hydrogel and the development of the drug delivery system are briefly introduced. The most promising three intelligent hydrogels in the human physiological environment, namely, pH responsiveness, temperature responsiveness, and pH/temperature dual responsiveness, are emphatically reviewed. Their release mechanisms, targeting transport, and controlled-prolonged release of drug are also discussed. In addition, some suggestions for the main problems and future development were given.


  • Open Access

    Metabolomics-Based Discovery of Molecular Signatures for Triple Negative Breast Cancer in Asian Female Population

    by Lixian Li, Xiaodong Zheng, Qi Zhou, Nathaniel Villanueva, Weiqi Nian, Xingming Liu, Tao Huan

    Triple negative breast cancer (TNBC) is a devastating cancer disease characterized by its poor prognosis, distinct metastatic patterns, and aggressive biological behavior. Research indicates that the prevalence and presentation of TNBC varies among races, with Asian TNBC patients more commonly presenting with large invasive tumors, high node positivity, and high histologic grade. In this work, we applied ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS)-based metabolomics to discover metabolic signatures in Asian female TNBC patients. Serum samples from 31 TNBC patients and 31 healthy controls (CN) were involved in this study. A total of 2860 metabolic features were detected in the serum samples. Among them, 77 metabolites, whose levels were significantly different between TNBC with CN, were confirmed. Using multivariate statistical analysis, literature mining, metabolic network and pathway analysis, we performed an in-depth study of the metabolic alterations in the Asian TNBC population. In addition, we discovered a panel of metabolic signatures that are highly correlated with the 5-year survival rate of the TNBC patients. This metabolomic study provides a better understanding of the metabolic details of TNBC in the Asian population.


  • Open Access

    HE4 as a biomarker for diagnosis of lung cancer

    by Yong-Peng He, Li-Xian Li, Jia-Xi Tang, Lin Yi, Yi Zhao, Hai-Wei Zhang, Zhi-Juan Wu, Hai-Ke Lei, Hui-Qing Yu, Wei-Qi Nian, et al.

    Background: The aim of our study was to assess the value of serum human epididymis protein 4 (HE4) to diagnose lung cancer and provide reliable scientific conclusions to guide clinical practice. Methods: A systematic search of the PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature, and WANFANG databases was conducted to identify all studies examining serum HE4 in the diagnosis of lung cancer published up to June, 2017. The Quality Assessment of Diagnostic Accuracy Studies tool was used to evaluate the methodological quality of each trial. The meta-analysis was performed using STATA software and Review Manager 5.3. Results: There were 21 studies involving 1883 cases and 1696 controls included in our meta-analysis. The pooled sensitivity and specificity of HE4 for diagnosing lung cancer were 0.73 (95% confidence interval [CI] 0.68–0.78) and 0.86 (95% CI 0.81–0.91), respectively. The positive likelihood ratio and negative likelihood ratio were 5.4 (95% CI 3.8–7.5) and 0.31 (95% CI 0.26–0.37), respectively. The diagnostic odds ratio was 17 (95% CI 12–26). The area under the curve of the summary receiver-operating characteristic curve was 0.86 (95% CI 0.83–0.89). Race, assay method, type of cancer, sample size, and publication date might be sources of heterogeneity in our meta-analysis. Subgroup analyses showed that the sensitivity in Caucasians was higher than that in Asians (0.81, 95% CI 0.71–0.91; and 0.71, 95% CI 0.66–0.77, respectively), but the specificity in Asians was better than that in Caucasians (0.87, 95% CI 0.81–0.92; and 0.85, 95% CI 0.73–0.97, respectively). The chemiluminescent microparticle immunoassay had the highest sensitivity, with 0.79 (95% CI 0.73–0.97), and the enzyme-linked immunosorbent assay had the highest specificity, with 0.87 (95% CI 0.79–0.94). HE4 had high diagnostic efficacy when screening for small cell lung cancer with the highest specificity (0.90, 95% CI 0.77–1.00). Conclusions: HE4 is a relatively promising and effective biomarker for the diagnosis of lung cancer. Furthermore, given the limitations of our study, additional large-scale and well-designed studies are needed in the future.